BR112022001488A2 - Inibidores de proteínas quinases de pirazolo-piridina substituída com heteroarila para promover regeneração do fígado ou redução ou prevenção de morte de hepatócitos - Google Patents

Inibidores de proteínas quinases de pirazolo-piridina substituída com heteroarila para promover regeneração do fígado ou redução ou prevenção de morte de hepatócitos

Info

Publication number
BR112022001488A2
BR112022001488A2 BR112022001488A BR112022001488A BR112022001488A2 BR 112022001488 A2 BR112022001488 A2 BR 112022001488A2 BR 112022001488 A BR112022001488 A BR 112022001488A BR 112022001488 A BR112022001488 A BR 112022001488A BR 112022001488 A2 BR112022001488 A2 BR 112022001488A2
Authority
BR
Brazil
Prior art keywords
pyridine
liver regeneration
prevention
reduction
hepatocyte death
Prior art date
Application number
BR112022001488A
Other languages
English (en)
Inventor
Bent Pfaffenrot
Roland Selig
Stefan Laufer
Wolfgang Albrecht
Original Assignee
Heparegenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heparegenix Gmbh filed Critical Heparegenix Gmbh
Publication of BR112022001488A2 publication Critical patent/BR112022001488A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

inibidores de proteínas quinases de pirazolo-piridina substituída com heteroarila para promover regeneração do fígado ou redução ou prevenção de morte de hepatócitos. a invenção refere-se aos compostos de pirazolo-piridina que inibem a proteína quinase quinase 4 ativada por mitógeno, (mkk4) e, em particular, inibem seletivamente mkk4 em relação às proteínas quinases jnk1 e mkk7. os compostos são úteis para promover a regeneração do fígado ou reduzir ou prevenir a morte de hepatócitos. os mesmos são ainda úteis para o tratamento de osteoartrite ou artrite reumatoide, ou doenças relacionadas ao cns.
BR112022001488A 2019-07-29 2020-07-27 Inibidores de proteínas quinases de pirazolo-piridina substituída com heteroarila para promover regeneração do fígado ou redução ou prevenção de morte de hepatócitos BR112022001488A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19188876 2019-07-29
EP20172253 2020-04-30
PCT/EP2020/071090 WO2021018820A1 (en) 2019-07-29 2020-07-27 Heteroaryl-substituted pyrazolo-pyridine protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death

Publications (1)

Publication Number Publication Date
BR112022001488A2 true BR112022001488A2 (pt) 2022-04-19

Family

ID=71894788

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001488A BR112022001488A2 (pt) 2019-07-29 2020-07-27 Inibidores de proteínas quinases de pirazolo-piridina substituída com heteroarila para promover regeneração do fígado ou redução ou prevenção de morte de hepatócitos

Country Status (11)

Country Link
US (1) US20220340561A1 (pt)
EP (1) EP4003991A1 (pt)
JP (1) JP2022544074A (pt)
KR (1) KR20220046584A (pt)
CN (1) CN114269745A (pt)
AU (1) AU2020320001A1 (pt)
BR (1) BR112022001488A2 (pt)
CA (1) CA3148780A1 (pt)
IL (1) IL290190A (pt)
MX (1) MX2022001115A (pt)
WO (1) WO2021018820A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019149738A1 (en) 2018-01-31 2019-08-08 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3810139A1 (en) 2018-06-21 2021-04-28 HepaRegeniX GmbH Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3823968A1 (en) 2018-07-16 2021-05-26 HepaRegeniX GmbH Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2023194443A1 (en) 2022-04-06 2023-10-12 Heparegenix Gmbh Pharmaceutical composition for the treatment of colon and lung cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037898A1 (en) * 2001-10-31 2003-05-08 Bayer Healthcare Ag Pyrimido [4,5-b] indole derivatives
WO2004058764A1 (en) * 2002-12-27 2004-07-15 Bayer Healthcare Ag 4-phenyl-pyrimido [4,5-b] indole derivatives
DK1893612T3 (da) 2005-06-22 2011-11-21 Plexxikon Inc Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere
PE20121126A1 (es) * 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2010111527A1 (en) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use
US8735436B2 (en) 2009-05-08 2014-05-27 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
BR112015028845A2 (pt) 2013-05-30 2017-07-25 Plexxikon Inc compostos para a modulação da quinase e indicações da mesma
KR20170102299A (ko) 2015-01-09 2017-09-08 길리어드 아폴로, 엘엘씨 비-알콜성 지방간 질환의 치료를 위한 acc 억제제 조합 요법
EP3414244A4 (en) 2016-02-12 2019-11-27 Pharmaxis Ltd. INHIBITORS OF LYSYL OXIDASES DERIVED FROM HALOGENOALLYLAMINE INDOLE AND AZAINDOLE AND USES THEREOF
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
WO2019149738A1 (en) * 2018-01-31 2019-08-08 Heparegenix Gmbh Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
RU2678455C1 (ru) * 2018-06-01 2019-01-29 Сергей Викторович Леонов Кристаллическая форма n-(3-(5-(4-хлорофенил)-1н-пиразоло[3,4-в]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамида, активный компонент, фармацевтическая композиция и лекарственное средство

Also Published As

Publication number Publication date
WO2021018820A1 (en) 2021-02-04
AU2020320001A1 (en) 2022-03-10
EP4003991A1 (en) 2022-06-01
US20220340561A1 (en) 2022-10-27
KR20220046584A (ko) 2022-04-14
CA3148780A1 (en) 2021-02-04
CN114269745A (zh) 2022-04-01
IL290190A (en) 2022-03-01
JP2022544074A (ja) 2022-10-17
MX2022001115A (es) 2022-05-03

Similar Documents

Publication Publication Date Title
BR112022001488A2 (pt) Inibidores de proteínas quinases de pirazolo-piridina substituída com heteroarila para promover regeneração do fígado ou redução ou prevenção de morte de hepatócitos
MX2020007954A (es) Inhibidores de la proteina cinasa cinasa 4 activada por mitogeno (mkk4) para promover la regeneracion del higado o reducir o prevenir la muerte de los hepatocitos.
EA201891974A1 (ru) Ингибиторы связывания белка wdr5 с белками
BR112017022349A2 (pt) ?composto, composição, método, e, método para inibir uma proteína irak?
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
BR122021004223A8 (pt) Molécula de anticorpo, composição, sequência de nucleotídeo, vetor, molécula de anticorpo e uso de uma molécula de anticorpo
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
BR112012033658A2 (pt) derivados bipiridílicos úteis para o tratamento de doenças induzidas por quinases
MX2018001395A (es) Derivados de pirazol pirimidina y sus usos.
BRPI0606281A2 (pt) compostos orgánicos
EA202092581A1 (ru) Соединения, ингибирующие rip1, а также способы их получения и применения
MX2019008458A (es) Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.
MX2018016419A (es) Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
BR112018072168A2 (pt) compostos derivados da pirimidina como inibidores da quinase jak
MX2010006203A (es) Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina.
BRPI0519759A2 (pt) composiÇÕes farmacÊuticas
BR112021023824A2 (pt) Inibidor de proteína quinase dependente de dna
EA201990333A1 (ru) Соединения, композиции и способы лечения или предотвращения симптома, ассоциированного с подагрой или гиперурикемией
BR112022012179A2 (pt) Compostos de quinazolina substituída úteis como ativadores de célula t
EA202090572A1 (ru) ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ
BRPI0517737A (pt) inibidores de quinase
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: HEPAREGENIX GMBH (DE)